27 April 2017
News and Views
Links and Services
Published ahead of print, a study in the Alimentary Pharmacology & Therapeutics reports on the safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes.
Non-alcoholic fatty liver disease has reached epidemic proportions in type 2 diabetes.
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors